Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells

Overview
This study monitored anti-CAR antibody responses in rhesus macaques infused with CD4-MBL CAR/CXCR5 T cells. The therapeutic cells were expanded in G-Rex® 6-well plates prior to infusion. All treated animals developed anti-CAR antibodies, which correlated with limited in vivo persistence of the CAR T cells.
What this paper found
All nine rhesus macaques infused with SIV-specific CD4-MBL CAR/CXCR5 T cells developed anti-CAR IgG antibodies in serum, detected by a flow cytometry binding assay. Binding at 28 days after treatment ranged from 0.5% to 27% of target cells, and control animals showed none. Blocking CD4 with an antibody reduced or eliminated binding in all six animals tested, which points to the CD4 domains as the main antigenic site. Binding to CAR targets with the CD28 extracellular domain replaced was lower with serum from 2 of 3 animals. Most sera also triggered NK-cell degranulation in an ADCC assay. Antibody levels did not correlate significantly with CAR T cell persistence or with infused dose.
Note: Preclinical study in rhesus macaques; the authors note that additional animals may be needed to assess the effect of the anti-drug antibody response on in vivo persistence.
This study shows that an anti-drug antibody (ADA) response can occur even when using self-proteins, likely due to novel epitopes created by abridged self-proteins — Brianna C. Davey, Mary S. Pampusch, Emily K. Cartwright, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Edward A. Berger, Pamela J. Skinner, Frontiers in Immunology
Study details
- Authors
- Brianna C. Davey, Mary S. Pampusch, Emily K. Cartwright, Hadia M. Abdelaal, Eva G. Rakasz, Aaron Rendahl, Edward A. Berger, Pamela J. Skinner
- Institution
- Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States · Wisconsin National Primate Research Center, University of Wisconsin, Madison, Madison, WI, United States · Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
- Journal
- Frontiers in Immunology
- Year
- 2022
- G-Rex® model(s)
- G-Rex®6 Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Infectious disease
- Study phase
- Preclinical
How G-Rex® was used
Rhesus PBMCs were stimulated with anti-CD3 and anti-CD28 for two days and transduced with the CD4-MBL CAR/CXCR5 gammaretroviral vector. The transduced cells were then placed in G-Rex® 6 well plates and expanded for 4 days before infusion into rhesus macaques.
Note: Mock-transduced cells underwent the same stimulation and expansion without exposure to the gammaretroviral vectors.
Explore related
Full citation
Davey BC, Pampusch MS, Cartwright EK, et al. Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells. Front Immunol. 2022;13:1032537.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.